Anzeige
Mehr »
Freitag, 26.12.2025 - Börsentäglich über 12.000 News
Prof. Dr. Dr. Andreas Pfützner: Geniale Lösung für Diabetiker!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
278 Leser
Artikel bewerten:
(0)

Physicists and Clinicians at Leading Dutch Cancer Center Report Advances in Stereotactic Lung Tumor Treatments Using RapidArc Radiotherapy from Varian

AMSTERDAM, Nov. 30 /PRNewswire-FirstCall/ -- Researchers from VU University Medical Center in Amsterdam have reported that RapidArc® radiotherapy from Varian Medical Systems has clinical advantages over earlier fixed-beam approaches to stereotactic treatments of lung tumors. Their findings, based on treatment of 85 medically inoperable lung cancer patients, were reported at the recent annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago and a condensed version has been published in the 'Green Journal' (Radiotherapy and Oncology) 93 (2009).

"RapidArc enabled much faster treatment for these patients, with treatment in just six minutes, reducing the risk of patient motion and achieving superior dose conformity around the target while reducing dose to the chest wall by almost a third," says Dr. Wilko Verbakel, medical physicist. "Dose conformity is extremely important when you are treating close to critical structures and the conformity you see with RapidArc is always better or at least as good as with fixed-beam IMRT and certainly better than achievable with ten static non-coplanar beams or dynamic conformal arc."

Clinicians at VU deliver stereotactic RapidArc treatments using the Novalis Tx(TM) radiosurgical platform from Varian and BrainLAB. The high dose delivery capability of Novalis Tx combined with the speed of RapidArc enables stereotactic treatments with beam-on time of as little as six and a half minutes, even for the highest doses, which previously took about 30 minutes to deliver.

Hypo-fractionated stereotactic lung treatments at VU are delivered in three sessions of 18 Gy each, five sessions of 11 Gy each or eight sessions of 7.5 Gy each, depending on the size and position of the tumor. Planning, described by Dr. Verbakel as 'very easy' using RapidArc, is based on 4D CT scans and the treatment field allows a small margin to account for tumor motion caused by breathing. Additional recent research by the team at VU has shown that, unlike with some other advanced radiation delivery techniques, treatment of a moving tumor with RapidArc has no negative dosimetric consequences.

RapidArc®, Varian's technology for delivering volumetric modulated arc therapy (VMAT), enables clinicians to deliver a highly-precise image-guided intensity-modulated treatment quickly, often with as little as one or two revolutions of the treatment machine around the patient. This enables treatments that are up to eight times faster than alternative approaches.

Professor Suresh Senan, radiation oncologist at VU, adds, "We are very encouraged by these findings and RapidArc is now our standard technique for all patients with stage 1 lung tumors."

*This research received grant support from Varian Medical Systems.

Editorial Contact: Neil Madle, Varian Medical Systems, +44 7786 526068, neil.madle@varian.com

W.F.A.R. Verbakel, S. Senan, C. Ong, J.P. Cuijpers, B.J. Slotman, F.J. Lagerwaard Rapid Delivery of Stereotactic Radiotherapy for Peripheral Lung Tumors using Volumetric Intensity Modulated Arcs - Radiother Oncol. 2009 Oct;93(1): 122-4. Available here: http://www.thegreenjournal.com/article/PIIS0167814009002709/abstract The abstract from ASTRO is available here: http://www.redjournal.org/article/S0360-3016(09)01321-2/fulltext

ABOUT VARIAN MEDICAL SYSTEMS

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,100 people who are located at manufacturing sites in North America, China, and Europe and in its 79 sales and support offices around the world. For more information, visit http://www.varian.com/

Varian Medical Systems, Inc.

CONTACT: Neil Madle of Varian Medical Systems, +44 7786 526068,
neil.madle@varian.com

Web Site: http://www.varian.com/

© 2009 PR Newswire
Renditeturbo 2026 - 5 Aktien mit Potenzial
2025 neigt sich dem Ende zu, ohne klassische Jahresendrallye, aber mit einem DAX, der viele Kritiker Lügen gestraft hat. Über 21 Prozent Kursplus seit Jahresbeginn, stärker als der US-Markt. Wer hätte das noch vor Monaten erwartet?

Genau solche Entwicklungen machen den Reiz der Börse aus. Denn auch 2026 dürfte wieder alles anders kommen als gedacht. Während viele Analysten weiter steigende Kurse erwarten, rückt eine zentrale Frage in den Fokus: Wo entstehen im kommenden Jahr echte Überraschungen, und wie kann man davon profitieren?

Unser aktueller Spezialreport beleuchtet fünf Entwicklungen, mit denen kaum jemand rechnet, die aber enormes Renditepotenzial bergen. Vom Comeback der Ölwerte über unterschätzte Plattform-Aktien bis hin zur möglichen Wachablösung im KI-Sektor: Wer 2026 überdurchschnittlich abschneiden will, muss antizyklisch denken und frühzeitig Position beziehen.

Im kostenlosen Report stellen wir 5 Aktien vor, die 2026 im Zentrum solcher Wendepunkte stehen könnten. Solide bewertet, gut positioniert und mit überraschend starkem Momentum.

Jetzt kostenlos herunterladen! Bevor andere erkennen, wo die Chancen wirklich liegen!

Dieses exklusive PDF ist nur für kurze Zeit verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.